13F Holdings
中文EN

GKOS GLAUKOS Corp

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1192448 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY46.9%
TTM net income YoY-93.8%
TTM EPS YoY-91.6%
Revenue 3-yr CAGR31.5%
Net income 3-yr CAGR—

Margins

Gross margin64.8%
Operating margin-25.5%
Net margin-24.6%
FCF margin5.2%
EBITDA margin-19.5%

Returns

ROE-22.8%
ROA-17.2%
ROIC (approx.)-22.8%
Asset turnover0.70x

Leverage & solvency

Liabilities / assets26.8%
Debt / equity0.00x
Current ratio4.57x
Interest coverage-36.57x

Cash quality & payout

Operating cash flow / net income-0.28x
Accruals ratio-22.0%
Payout ratio—
Capex / revenue1.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$211.03M$185.61M$150.57M$143.12M$133.54M$124.12M$106.66M$105.50M
Cost of revenue$31.16M$34.02M$33.34M$31.77M$28.83M$26.90M$24.32M$28.64M
Gross profit$179.87M$151.59M$117.23M-$1.52M$104.71M$97.22M$82.35M$76.86M
R&D expense$30.95M$51.30M$44.15M$43.65M$26.86M$36.54M$32.35M$36.53M
SG&A expense$130.94M$116.06M$92.94M$94.70M$83.00M$83.38M$70.67M$69.00M
Operating income$828,000-$17.27M-$19.86M-$139.87M-$16.36M-$22.69M-$20.68M-$28.67M
Interest expense$1.09M$1.46M$1.12M$1.15M$1.18M$1.15M$1.16M$1.57M
Pretax income$2.32M-$17.72M-$19.30M-$139.82M-$16.00M-$19.41M-$17.82M-$33.69M
Income tax$303,000$656,000$484,000-$6.16M$234,000$248,000$326,000-$114,000
Net income$2.02M-$18.38M-$19.78M-$133.66M-$16.23M-$19.66M-$18.15M-$33.58M
EBITDA$9.78M-$8.40M-$8.06M-$127.70M-$7.23M-$14.12M-$12.45M-$19.93M
EPS (basic)0.03-0.31-0.34—-0.28-0.34-0.32—
EPS (diluted)0.03-0.31-0.34—-0.28-0.34-0.32—
Weighted avg. shares (diluted)61.20M58.82M58.02M—57.40M57.20M56.64M—
Balance sheet
Cash & equivalents$162.33M$114.48M$104.25M$90.81M$102.08M$104.65M$118.98M$174.36M
Receivables$150.00M$138.90M$119.69M$108.61M$98.68M$82.98M$71.53M$60.74M
Inventory$61.03M$59.31M$62.38M$63.56M$63.86M$64.62M$59.46M$57.68M
Current assets$579.65M$515.78M$485.75M$474.98M$454.77M$436.06M$444.54M$449.79M
PP&E, net$112.07M$112.11M$112.43M$113.25M$110.94M$111.82M$96.81M$97.87M
Goodwill$66.71M$66.71M$66.71M$66.71M$66.71M$66.71M$66.13M$66.13M
Intangibles$121.26M$127.15M$133.03M$141.92M$264.14M$270.49M$257.87M$263.44M
Total assets$979.53M$920.52M$893.33M$893.49M$999.38M$986.96M$966.18M$974.76M
Current liabilities$126.73M$102.33M$89.42M$101.28M$87.52M$79.14M$68.53M$75.12M
Total liabilities$262.25M$238.03M$222.40M$237.33M$229.84M$221.85M$202.22M$207.82M
Shareholders' equity$717.27M$682.49M$670.93M$656.15M$769.54M$765.11M$763.96M$766.93M
Shares outstanding59.17M58.86M58.36M57.51M57.39M57.25M56.74M56.44M
Cash flow statement
Operating cash flow$38.57M$14.82M-$12.53M$6.84M-$10.09M$6.98M-$18.52M$507,000
Capital expenditure$2.08M$2.74M$3.96M$2.91M$1.64M$1.18M$1.94M$1.73M
Free cash flow$36.49M$12.09M-$16.48M$3.93M-$11.72M$5.80M-$20.46M-$1.23M
Investing cash flow-$5.54M-$5.31M$10.50M-$15.89M-$3.99M-$20.78M-$36.95M$11.79M
Financing cash flow$14.69M$991,000$15.77M$2.43M$5.26M$2.25M$1.95M$60.11M
Depreciation & amortization$8.95M$8.87M$11.80M$12.16M$9.13M$8.57M$8.23M$8.74M
Stock-based compensation$17.77M$28.86M$19.14M$17.30M$14.91M$18.02M$12.99M$13.31M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.